Table 1.
Demographics of patients with endometrial carcinoma.
| Mean ± SD | |
|---|---|
| Age | 55.77 ± 9.56 |
| BMI | 26.32 ± 4.62 |
| Serum calcium | 9.18 ± 0.72 |
| Ionized serum calcium | 8.89 ± 0.69 |
| Serum albumin | 43.60 ± 4.19 |
| N (%) | |
|---|---|
| Ascites cytology | |
| Negative | 352 (90.96%) |
| Positive | 35 (9.04%) |
| FIGO stage | |
| I | 406 (79.61%) |
| II | 25 (4.90%) |
| III | 64 (12.55%) |
| IV | 15 (2.94%) |
| Lymph node metastasis | |
| Negative | 463 (90.78%) |
| Positive | 47 (9.22%) |
| LVSI | |
| Negative | 414 (83.30%) |
| Positive | 83 (16.70%) |
| Tumor grade | |
| 1 | 171 (33.53%) |
| 2 | 220 (43.14%) |
| 3 | 119 (23.33%) |
| Histology | |
| EEA | 440 (86.28%) |
| Other types | 70 (13.73%) |
SD, standard deviation; BMI, body mass index; LVSI, lymph-vascular space invasion, EEA, endometriod endometrial adenocarcinoma; other types include serous endometrial cancer, mixed endometrioid and serous carcinoma, and clear cell carcinoma.